医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Germany-Based TMK Architekten Joins HDR Architecture, Strengthening the World’s No. 1 Healthcare and Science + Technology Design Firm

2013年03月04日 PM11:25
このエントリーをはてなブックマークに追加


 

OMAHA, Neb. & DÜSSELDORF, Germany

TMK Architekten • Ingenieure, one of Germany’s leading healthcare architecture firms, announced today that it is joining forces with HDR Architecture, the world’s No. 1 healthcare and science + technology design firm. The merged company will conduct business as HDR TMK, and will be the hub for the firm’s healthcare and science + technology design programs in Europe.

TMK joins the HDR family with nearly 200 employees located in offices in Berlin, Dortmund, Duesseldorf, Erfurt, Kiel, and Leipzig, Germany. Since its foundation more than 50 years ago, the firm has designed more than 1,500 healthcare projects throughout Europe, ranging from large-scale replacement hospitals to community clinics, surgical centers and outpatient facilities. The firm is well-known as an innovator in designing contemporary buildings for health—buildings that are distinctively designed to focus on people and to aid in the healing process.

“This is an exciting announcement for both HDR and TMK and a key part of our global strategy,” says Doug Wignall, president of HDR Architecture. “As a firm, HDR has made a commitment not only to designing projects all over the world and bringing the best ideas from around the globe to our clients, but to establishing a permanent presence in strategic locations around the globe. We are excited about the opportunity to blend the unique perspective that TMK offers as a German healthcare practice into HDR’s global team of thought leaders from North America, the Middle East and the Pacific Rim.”

Reflecting on the merger of the practices, Guido Messthaler, a Senior Partner with TMK Architekten, notes that, “Both firms are compatible on many levels, specifically in our commitment to our clients and to design excellence.” He continues, “The merger will deepen our healthcare expertise and enable us to reach deeper in the European marketplace. And with access to HDR’s expertise and portfolio, we will also be able to further develop work in the science and technology and higher education markets.”

HDR Architecture employs more than 1,300 professionals in 44 offices worldwide, including offices in the U.S., Canada, China, Europe, the Middle East and Australia. Global acquisitions are a key part of the firm’s growth strategy; with the addition of TMK, over 20% of HDR Architecture’s employees are located outside of the United States.

About HDR Architecture

HDR Architecture is a part of the HDR, Inc. family, a global architecture, engineering and consulting firm with more than 8,000 professionals in 190 locations worldwide. The architecture practice is an industry leader in designing technologically complex buildings and infrastructure; it is ranked as the No. 1 healthcare and science + technology design firm in the “World Architecture 100” ranking. Recent projects in Europe include the new Roslin Institute Building at the University of Edinburgh in Midlothian, Scotland; the Iberian Nanotechnology Laboratory in Braga, Portugal; and multiple projects for the Pirbright Institute in Surrey, United Kingdom. In addition to the newly acquired TMK offices in Germany, HDR has a design studio in London, UK. Visit www.hdrinc.com

CONTACT

HDR Architecture
Michael McManus, 206-826-4712
michael.mcmanus@hdrinc.com

同じカテゴリーの記事 

  • ENHERTU® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in HR Positive, HER2 Low Metastatic Breast Cancer Following One or More Lines of Endocrine Therapy in DESTINY-Breast06 Phase 3 Trial
  • PROTEINA Initiates Global Clinical Validation Project with Emory University School of Medicine, USA
  • AriBio 获得欧洲药品管理局对AR1001治疗阿尔茨海默病3期临床试验(POLARIS-AD)的授权
  • AriBio Receives EMA Phase 3 Clinical Trial Authorisation for AR1001 in Treatment of Alzheimer’s Disease (POLARIS-AD)
  • ReNAgadeセラピューティクス、GanNA Bioと糖鎖生物学に対するコミットメントを継続